Metoprolol beta-blockers

Description Results NMA

all cause death 0.87 [0.69; 1.11]

all cause death 1.04 [0.07; 15.74]

all cause death NaN [NaN; NaN]

all cause death 1.00 [0.51; 1.94]

all cause death 0.64 [0.44; 0.95]

reinfarction 0.65 [0.43; 0.98]

all cause death 0.93 [0.70; 1.23]

cardiovascular death 0.93 [0.69; 1.26]

Sudden death 0.85 [0.48; 1.49]

cardiac death 0.98 [0.72; 1.32]

all cause death 0.58 [0.26; 1.28]

reinfarction 0.55 [0.32; 0.95]

all cause death 0.77 [0.48; 1.24]

Sudden death 0.41 [0.18; 0.93]

all cause death 0.79 [0.55; 1.13]

cardiac death 0.84 [0.57; 1.25]

Metoprolol (initial dose intravenously) (n=2877)

vs.

(n=2901)

Double

Sample size: 2877/2901

Primary endpoint:

FU duration: 15 days

Metoprolol (initial dose intravenously) (n=25)

vs.

(n=26)

Double

Sample size: 25/26

Primary endpoint:

FU duration: 14 days

Practolol, (initial dose intravenously) H87/07, or metoprolol (n=38)

vs.

(n=45)

Double

Sample size: 38/45

Primary endpoint:

FU duration: 1 week

Metoprolol (initial dose intravenously) (15 mg) (n=696)

vs.

(n=694)

No

Sample size: 696/694

Primary endpoint:

FU duration: 5 days

Metoprolol 100mg twice daily (initial dose intravenously) (n=698)

vs.

placebo (n=697)

Double blind

Parallel groups

Sample size: 698/697

Primary endpoint: all cause death

FU duration: 2 years

Metoprolol 100 mg bid (n=1195)

vs.

placebo (n=1200)

treatment continued for up to 1 year

Double blind

Parallel groups

Sample size: 1195/1200

Primary endpoint: all-cause mortality

FU duration: 18 months

Metoprolol 100mg twice daily (n=273)

vs.

placebo (n=280)

Double blind

Parallel groups

Sample size: 273/280

Primary endpoint: NA

FU duration: 1 year

Metoprolol 100mg twice daily (n=154)

vs.

placebo (n=147)

Double blind

Parallel groups

Sample size: 154/147

Primary endpoint: NA

FU duration: 36 months

Metoprolol 100 mg twice daily for one year (initial dose intravenously) (n=416)

vs.

placebo (n=384)

Double blind

Parallel groups

Sample size: 416/384

Primary endpoint: NA

FU duration: 1 year

Withdrawals due to adverse effects 3.33 [1.37; 8.12]

all cause mortality ∞ [NaN; ∞]

Pro-arrhythmia ∞ [NaN; ∞]

Atrial fibrillation recurrence 0.91 [0.79; 1.04]

Metoprolol 100 mg/d (n=197)

vs.

placebo (n=197)

double blnd

Parallel groups

Sample size: 197/197

Primary endpoint:

FU duration: 6 months

All deaths 0.81 [0.57; 1.15]

Fatal and nonfatal MI 1.30 [0.69; 2.46]

metoprolol CR/XL (n=495)

vs.

placebo (n=490)

double-blind

Parallel groups

Sample size: 495/490

Primary endpoint: all-cause death

FU duration: 1y

NYHA deterioration 0.87 [0.34; 2.20]

all cause death 1.07 [0.61; 1.86]

death or HF hospitalisation 0.77 [0.56; 1.06]

hospitalisation for heart failure 0.74 [0.50; 1.07]

NYHA improvement 1.26 [0.93; 1.70]

all cause death 0.67 [0.55; 0.82]

cardiovascular death 0.63 [0.51; 0.78]

Sudden death 0.60 [0.46; 0.79]

All cause death 0.91 [0.75; 1.11]

metoprolol target dose 100-150 mg daily (dose divided into two or three per day) (n=194)

vs.

placebo (n=189)

Double blind

Parallel groups

Sample size: 194/189

Primary endpoint: death or transplantation waiting list

FU duration: 18 months

metoprolol CR/XL at target dose of 200 mg once daily (n=1990)

vs.

placebo (n=2001)

Double blind

Parallel groups

Sample size: 1990/2001

Primary endpoint: all-cause death

FU duration: 1 y

metoprolol (n=9)

vs.

placebo (n=16)

Sample size: 9/16

Primary endpoint: Exercise tolerance

FU duration: 12 mo

metoprolol (n=25)

vs.

placebo (n=25)

Sample size: 25/25

Primary endpoint: Exercise tolerance

FU duration: 6 mo

metoprolol (n=15)

vs.

placebo (n=9)

Sample size: 15/9

Primary endpoint: Hemodynamics

FU duration: 3 mo

metoprolol CR 200 mg/d (n=214)

vs.

placebo (n=212)

Double aveugle

Parallel groups

Sample size: 214/212

Primary endpoint:

FU duration: 6 mo

Metoprolol (n=1092)

vs.

placebo (n=0)

Sample size: 1092/0

Primary endpoint:

FU duration: